Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70149 | 0.82 | ALDH1A1 (0.42) | ALDH1A1IRAK4XDHKMT2ALCK | |
| SCHEMBL71552 | 0.77 | ALDH1A1 (0.44) | ALDH1A1IRAK4XDHKMT2ATAS2R14 | |
| SCHEMBL18309195 | 0.73 | ALDH1A1 (0.57) | ALDH1A1IRAK4XDHKMT2ALCK | |
| SCHEMBL30484501 | 0.73 | IRAK4 (0.49) | ALDH1A1IRAK4KMT2ATAS2R14KDM4E | |
| SCHEMBL1791404 | 0.71 | ALDH1A1 (0.47) | ALDH1A1IRAK4XDHKMT2ALCK | |
| SCHEMBL7804048 | 0.71 | KEAP1 (0.37) | ALDH1A1KMT2ATAS2R14KDM4ENPC1 | |
| SCHEMBL7007318 | 0.70 | ALDH1A1 (0.46) | ALDH1A1KMT2AKDM4EKAT6A | |
| SCHEMBL16692253 | 0.69 | ALDH1A1 (0.49) | ALDH1A1IRAK4XDHKMT2AKDM4E | |
| SCHEMBL71164 | 0.69 | ALDH1A1 (0.45) | ALDH1A1IRAK4KMT2ALCKFYN | |
| SCHEMBL18304665 | 0.69 | ALDH1A1 (0.57) | ALDH1A1KMT2AKDM4EKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129537-B2 | Compounds as PDE IV and TNF inhibitors | RHONE-POULENC RORER LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-7652144-B2 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-7045660-B2 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-04-20 | — | — | US | disclosed |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | FENTON GARRY (GB) | 2003-01-16 | — | — | US | disclosed |
| US-6472412-B1 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2002-10-29 | — | — | US | disclosed |
| EP-0711282-B1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | AVENTIS PHARMA LTD (GB) | 2002-06-05 | — | — | EP | disclosed |
| EP-0711282-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004045-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE4C | ALDH1A1 1572/4885IRAK4 183/4885XDH 751/4885 |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | ALDH1A1 1357/4885IRAK4 145/4885XDH 527/4885 |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | ALDH1A1 1364/4885IRAK4 159/4885XDH 564/4885 |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | ALDH1A1 1364/4885IRAK4 159/4885XDH 564/4885 |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | ALDH1A1 1357/4885IRAK4 145/4885XDH 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.